Pedro Uson Junior, MD retweetledi
#ICYMI: Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study by @PedroUson, Samadder et al. bit.ly/3suiltv
English
Pedro Uson Junior, MD
25 posts
Pedro Uson Junior, MD
@PedroUson
GI cancer medical oncologist
Phoenix, AZ Katılım Mayıs 2020
143 Takip Edilen145 Takipçiler
Pedro Uson Junior, MD retweetledi
>15% of #patients w/ #gastriccancer #GEJcancer & #esophagealcancer had #germline PGVs
80% w/ #PARPi #clinicaltrial/management implications
80% missed by @NCCN
#INTERCEPT @PedroUson @J_Samadder @MayoCancerCare @Invitae @DDS_Journal @springerpub
link.springer.com/article/10.100…
English
Pedro Uson Junior, MD retweetledi
Hot off the Press ...
Circulating Cell-Free Tumor DNA in Advanced #PancreaticCancer identifies Patients With Worse Overall Survival frontiersin.org/article/10.338…
@PedroUson @the_danielahn @drjasonstarr @MiteshBorad @kmody29 @sonbol_bassam @MayoCancerCare @FrontOncology
English
Português
O oncologista @PedroUson é 1° autor de estudo prospectivo multicêntrico publicado na Cancer Prevention Research que buscou determinar a prevalência de variantes patogênicas da linhagem germinativa no CA hepatobiliar - tinyurl.com/2zw5brma #ONCONEWS
Português
Pedro Uson Junior, MD retweetledi
@Aiims1742 thank you for sharing the findings of this paper in #pancreaticcancer
@MayoCancerCare @PedroUson
Anirban Maitra@Aiims1742
Clinical Impact of Pathogenic Germline Variants in #PancreaticCancer journals.lww.com/ctg/Fulltext/2… All 3 @MayoClinic campuses conducted this study following the @NCCN universal germ line testing guidelines ~15% patients had pathogenic germline variants (BRCA2/ATM most common)
English
O oncologista brasileiro @PedroUson, pesquisador fellow na Mayo Clinic, é 1º autor de estudo publicado na Clinical Gastroenterology and Hepatology que corrobora evidências da predisposição hereditária ao câncer colorretal - tinyurl.com/4c4whu92 #COLORRETAL #GI #ONCONEWS
Português
Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: A multi-center prospective study cghjournal.org/article/S1542-…
English
Great robust thoughtful discussion
Pedro Uson Junior, MD@PedroUson
@HalletJulie @SyedAAhmad5 @JournalofGISurg @timpawlik @HodinRichard @NZyromski @JBMatthews @TomVargheseJr @SWexner @DrNCoburn @VGupta_MD I think it is an absurd reviewers making opinions based on gender, sex and country/ institution of the authors. Double blinding the best for sure
English
@SyedAAhmad5 @JournalofGISurg @timpawlik @HodinRichard @NZyromski @JBMatthews @TomVargheseJr @SWexner Blinding only one side of the process is problematic. Unblinding reviewers comes w other problems, especially for junior reviewers. Double blinding may be best. Like this piece by @DrNCoburn @VGupta_MD on that issue 👉 journals.lww.com/annalsofsurger…
English
@HalletJulie @SyedAAhmad5 @JournalofGISurg @timpawlik @HodinRichard @NZyromski @JBMatthews @TomVargheseJr @SWexner @DrNCoburn @VGupta_MD I think it is an absurd reviewers making opinions based on gender, sex and country/ institution of the authors. Double blinding the best for sure
English
As an Associate Editor of @JournalofGISurg I see a lot of different styles of reviewers. One that has intrigued me is reviewers signing their names so there is transparency. Should more reviewers do this? @timpawlik @HodinRichard @NZyromski @JBMatthews @TomVargheseJr @SWexner
English
Pedro Uson Junior, MD retweetledi
Pedro Uson Junior, MD retweetledi
@agrothey @VPrasadMDMPH No perfect trial design. Limited options in PDAC. POLO trial adds one more and supports a precedent from other BRCA-related cancers. A nicer option over chemotherapy for most patients on a longitudinal basis. A start point to build upon...
Axel Grothey@agrothey
@VPrasadMDMPH @lauraelee @MiteshBorad Vinay, please.... I have been critical of the POLO trial @EileenMOReilly but this is not “criminal”. We are all trying to move science forward - and POLO with all its faults does that. @OncoAlert
English
Pedro Uson Junior, MD retweetledi
Last but not least #ESMO20 CheckMate577
Given the complex study cohort enrolling >700 patients is a huge accomplishment! Global study 🌎 🤝
Primary endpoint DFS (secondary OS).
Primary endpoint reached with HR 0.69
@OncoAlert 🚨 #immunotherapy
Munich, Germany 🇩🇪 English
Pedro Uson Junior, MD retweetledi
Practice changing 3 month+ OS gain for CPS5 patients in CheckMate649 🏆🏆🏆 Biggest study ever in #stomachcancer! Breaking through the one year barrier is meaningful in gastric cancer trials. #ESMO2020
English
Pedro Uson Junior, MD retweetledi
#Pancsm #ESMO20
#PancreaticCancer remains a devastating disease.
See data presented by @EileenMOReilly discussing negative trials in #pancsm & a potential ways forward.
@OncoAlert 🚨
Munich, Germany 🇩🇪 English
@PestanaRC Agree, probably for all MSI-H GI cancers ICI will be better on 1st line, we just don't have the data yet
English
KEYNOTE-177 shows improved QoL in MSI-H CRC pts receiving Pembrolizumab versus chemotherapy.
In fellowship I learned we have 2 goals treating metastatic disease: (1) improve OS (2) improve QoL.
Is this enough for everyone to agree pembro should be 1L for these pts?
#ESMO20
GTG@GrupoGTG
Andre et al, KEYNOTE-177 QoL results Pembro vs standard chemotherapy in MSI-H/dMMR mCCR: - better health-related QoL - prolonged TTD for global health status/QoL (HR 0.61), physical functioning (HR 0.50), social functioning (HR 0.53) and fatigue (HR 0.48) #ESMO20
English
Pedro Uson Junior, MD retweetledi
Results: CCTG PA.7 in #pancreas #cancer of randomized Gemzar + Nab-P +/- Durvalumab + Treme with no difference in OS (8.8M vs. 9.8M), PFS of (5.4M vs. 5.5M), or RR = 23% vs. 33%. #ESMO20
@PanCAN #clinicaltrials #CancerResearch @VUMC_Cancer @VUMChealth @OncoAlert #immunotherapy
English
Pedro Uson Junior, MD retweetledi
@myESMO Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial #ESMO20 by Dr Come Lepage
@OncoAlert @PedroUson @OPENoncology @Epigenomica_mx @trials4now @Kristel_GT
English
@liveRPancSurg @rcarvalhoonco Awaiting randomized trial, but we should be careful with the term local recurrence, could be a new primary tumor or even metastatic spread. DOI: 10.1158/2159-8290 cancerdiscovery.aacrjournals.org/content/10/6/7…
English
@rcarvalhoonco Don’t think it’s that straightforward. A proportion of patients will have local only recurrence, and it is not clear that systemic Rx will improve local control for resectable lesions. Main benefit of NAT is to test biology but there is no RCT data pubmed.ncbi.nlm.nih.gov/32046922/
English
I strongly disagree w/ this statement. #PancreaticCancer is a systemic disease. Surgery upfront is an option only for low risk tumors (<2-30mm, cN0, Ca19-9 not high - cutoff is unknown). For all the others (majority), we should give neoadj Tx (regimen? Sequence? RT?). #GDUGI2020
bhawna sirohi@SirohiBhawna
#GDUGI2020 convincing argument by dr choti in favour of upfront surgery for resectable pancreas ca. Would prefer neoadjuvant chemotherapy..@agrothey @pashtoonkasi @Shrikhande_SV @SyedAAhmad5 @MarcBesselink @IHPBA good question- Shd we continue NACT till nadir of ca19.9 reached?
Sao Paulo, Brazil 🇧🇷 English
@KellyBorgesAra2 Esse mesmo, OS e dados de Mab usado no braço controle do KN 177 serao importantes
Português
@PedroUson Interessante! Não sabia dessa análise de subgrupos do CALGB. Seria esse o paper?
ascopubs.org/doi/full/10.12…
Português
Relembrando #ASCO20 c/fantástico Keynote-177 e benefício pra Pembrolizumab em 1a linha de CCRm c/instabilidade microssatélite. Apenas lembrar de resistência primária em 30% pts e considerar QT em PS2, crise visceral. Consideraria risco de FP 10% /double test com PCR pós IHQ.
Português